Polycythemia vera is a rare condition that affects the bone marrow, which is slow to progress and typically develops in later life. It is a condition characterized by the overproduction of red blood ...

The investigators in a recent study found that prior thrombotic events and leukocytosis were linked to subsequent thrombotic events in general, and prior arterial events and hyperlipidemia were linked ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

Rusfertide significantly improves hematocrit control and reduces the mean number of phlebotomies in patients who are phlebotomy-dependent despite standard care. The Food and Drug Administration (FDA) ...

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...

LIVER tumors, usually hepatomas, are relatively frequent in cases of hepatic cirrhosis, occurring in approximately 3 or 4 per cent of patients with alcoholic cirrhosis and in a somewhat higher ...

The SANRECO study investigates divesiran for polycythemia vera, focusing on regulating iron metabolism to control red blood cell production. Current PV treatments include therapeutic phlebotomy, ...

Polycythemia vera is the ultimate phenotypic consequence of the V617F mutation in Janus kinase 2 (encoded by JAK2), but the extent to which this mutation influences the behavior of the involved CD34+ ...

Background A 16-year-old white male with a history of obstructive uropathy presented to a pediatric outpatient clinic with a first syncope. At presentation, he had a hemoglobin level of 220 g/l, a ...

Los Angeles, USA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Polycythemia Vera Pipeline Report presents an Updated Clinical Data of all the companies working in the Polycythemia Vera drug development scenario.

Dublin, Feb. 17, 2025 (GLOBE NEWSWIRE) -- The "Polycythemia Vera - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report ...